{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:54:24Z","timestamp":1790553264185,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ctrv.2021.102170","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T12:16:50Z","timestamp":1614341810000},"page":"102170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"special_numbering":"C","title":["Targeting FGFR inhibition in cholangiocarcinoma"],"prefix":"10.1016","volume":"95","author":[{"given":"Lipika","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9767-4906","authenticated-orcid":false,"given":"Sarinya","family":"Kongpetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-4051","authenticated-orcid":false,"given":"Valerie E.","family":"Crolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-1604","authenticated-orcid":false,"given":"John","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctrv.2021.102170_b0005","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1158\/0008-5472.CAN-13-1911","article-title":"Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma","volume":"74","author":"Guest","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102170_b0010","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2021.102170_b0015","unstructured":"American Cancer Society. Survival Rates for Bile Duct Cancer Where do these numbers come from? 2020. https:\/\/www.cancer.org\/cancer\/bile-duct-cancer\/detection-diagnosis-staging\/survival-by-stage.html."},{"issue":"9","key":"10.1016\/j.ctrv.2021.102170_b0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2021.102170_b0025","unstructured":"Administration USF and D. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion. 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion."},{"issue":"2","key":"10.1016\/j.ctrv.2021.102170_b0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.gendis.2014.09.005","article-title":"Fibroblast growth factor (FGF) signaling in development and skeletal diseases","volume":"1","author":"Teven","year":"2014","journal-title":"Genes and Diseases"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102170_b0035","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102170_b0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102170_b0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","article-title":"Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach","volume":"179","author":"Presta","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102170_b0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102170_b0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102170_b0060","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102170_b0065","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discovery"},{"issue":"17","key":"10.1016\/j.ctrv.2021.102170_b0070","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102170_b0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21037\/cco.2019.08.14","article-title":"Systemic therapy for gallbladder cancer","volume":"8","author":"Javle","year":"2019","journal-title":"Chinese Clinical Oncology"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102170_b0080","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-on","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102170_b0085","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2021.102170_b0090","doi-asserted-by":"crossref","unstructured":"Sekiya S, Suzuki A. Brief report Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. The Journal of Clinical Investigation 2012;122. https:\/\/doi.org\/10.1172\/JCI63065DS1.","DOI":"10.1172\/JCI63065"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102170_b0095","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discovery"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102170_b0100","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2021.102170_b0105","doi-asserted-by":"crossref","unstructured":"Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, et al. Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. PLoS Genetics 2014;10. https:\/\/doi.org\/10.1371\/journal.pgen.1004135.","DOI":"10.1371\/journal.pgen.1004135"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102170_b0110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102170_b0115","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102170_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102170_b0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102170_b0130","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Reports"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102170_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype","author":"Jain","year":"2018","journal-title":"JCO Precision Oncology"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102170_b0140","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma","author":"Kongpetch","year":"2020","journal-title":"JCO Global Oncology"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102170_b0145","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nature","volume":"6","author":"Sia","year":"2015","journal-title":"Communications"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102170_b0150","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to atp-competitive FGFR inhibitors in patients with FGFR2 fusion\u2013positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discovery"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102170_b0155","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102170_b0160","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-1087-7","article-title":"BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1\/2 and JNK\/c-Jun pathways","volume":"9","author":"Chen","year":"2018","journal-title":"Cell Death Dis"},{"issue":"S1","key":"10.1016\/j.ctrv.2021.102170_b0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver International"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102170_b0170","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.32803","article-title":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012","volume":"126","author":"Florio","year":"2020","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102170_b0175","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102170_b0180","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/MOG.0000000000000162","article-title":"Genetics of Opisthorchis viverrini -related cholangiocarcinoma","volume":"31","author":"Jusakul","year":"2015","journal-title":"Current Opinion in Gastroenterology"},{"key":"10.1016\/j.ctrv.2021.102170_b0185","article-title":"Classification and management of hepatolithiasis: A high-volume, single-center\u2019s experience","author":"Feng","year":"2012151","journal-title":"Intractable & Rare Diseases Research"},{"key":"10.1016\/j.ctrv.2021.102170_b0190","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102170_b0195","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2021.102170_b0200","unstructured":"NCCN Guidelines Version 2.2020 Hepatobiliary Cancers. 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf."},{"key":"10.1016\/j.ctrv.2021.102170_b0205","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","article-title":"ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin \/ 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously-tr","volume":"37","author":"Lamarca","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102170_b0210","first-page":"200","article-title":"Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102170_b0215","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/jcm9010056","article-title":"Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization","volume":"9","author":"K\u00f6hler","year":"2019","journal-title":"Journal of Clinical Medicine"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102170_b0220","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102170_b0225","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14737140.2018.1491795","article-title":"Future applications of FGF\/FGFR inhibitors in cancer","volume":"18","author":"Ghedini","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102170_b0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2021.102170_b0235","doi-asserted-by":"crossref","unstructured":"Kalyukina M, Yosaatmadja Y, Middleditch MJ, Patterson A v., Smaill JB, Squire CJ. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. ChemMedChem 2019;14:494\u2013500. https:\/\/doi.org\/10.1002\/cmdc.201800719.","DOI":"10.1002\/cmdc.201800719"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102170_b0240","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102170_b0245","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102170_b0250","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102170_b0255","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1200\/JCO.2020.38.15_suppl.3603","article-title":"Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion","volume":"38","author":"Cleary","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102170_b0260","doi-asserted-by":"crossref","first-page":"TPS3157","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3157","article-title":"FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology","volume":"37","author":"Hyman","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102170_b0265","doi-asserted-by":"crossref","unstructured":"Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS ONE 2016;11. https:\/\/doi.org\/10.1371\/journal.pone.0162594.","DOI":"10.1371\/journal.pone.0162594"},{"key":"10.1016\/j.ctrv.2021.102170_b0270","unstructured":"Basilea Pharmaceuticals. Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA). 2020. https:\/\/www.globenewswire.com\/news-release\/2020\/07\/20\/2064138\/0\/e\u2026FIDES-01-with-derazantinib-in-bile-duct-cancer-iCCA.html."},{"key":"10.1016\/j.ctrv.2021.102170_b0275","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery & pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102170_b0280","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2019.37.15_suppl.4117","article-title":"Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations","volume":"37","author":"Park","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102170_b0285","doi-asserted-by":"crossref","unstructured":"Ochiiwa H, Fujita H, Itoh K, Sootome H, Hashimoto A, Fujioka Y, et al. Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities., American Association for Cancer Research (AACR); 2013, p. A270\u2013A270. https:\/\/doi.org\/10.1158\/1535-7163.targ-13-a270.","DOI":"10.1158\/1535-7163.TARG-13-A270"},{"issue":"22","key":"10.1016\/j.ctrv.2021.102170_b0290","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102170_b0295","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1\u20134 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102170_b0300","doi-asserted-by":"crossref","first-page":"v100","DOI":"10.1093\/annonc\/mdy149","article-title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors","volume":"29","author":"Meric-Bernstam","year":"2018","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102170_b0305","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2020.38.15_suppl.108","article-title":"FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements","volume":"38","author":"Goyal","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2021.102170_b0310","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2021.102170_b0315","doi-asserted-by":"crossref","unstructured":"Nogova L, Sequist L v., Garcia JMP, Andre F, Delord JP, Hidalgo M, et al. Evaluation of BGJ398, a Fibroblast growth factor receptor 1-3 kinase inhibitor, in patientswith advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: Results of a global phase I, dose-escalation and dose-expansion stud. Journal of Clinical Oncology 2017;35:157\u201365. https:\/\/doi.org\/10.1200\/JCO.2016.67.2048.","DOI":"10.1200\/JCO.2016.67.2048"},{"key":"10.1016\/j.ctrv.2021.102170_b0320","doi-asserted-by":"crossref","unstructured":"Javle, Milind M.; Roychodhury, Sameek; Kelley, Robin Kate; Sadeghi, Saeed; Macarulla, Teresa; Dirk-Thomas, Waldschmidt; Goyal L. Final results from a phase II study of infigratinib (BGJ398), an FGFRselective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J Clin Oncol 39: 2021 (Suppl; Abstr 265) 2021;39:66.","DOI":"10.1200\/JCO.2021.39.3_suppl.265"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102170_b0325","doi-asserted-by":"crossref","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2021.102170_b0330","doi-asserted-by":"crossref","unstructured":"Subbiah V, Barve M, Iannotti NO, Gutierrez M, Smith DC, Roychowdhury S, et al. Abstract A078: FIGHT-101: A phase 1\/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies, American Association for Cancer Research (AACR); 2019, p. A078\u2013A078. https:\/\/doi.org\/10.1158\/1535-7163.targ-19-a078.","DOI":"10.1158\/1535-7163.TARG-19-A078"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102170_b0335","doi-asserted-by":"crossref","first-page":"F1577","DOI":"10.1152\/ajprenal.00463.2006","article-title":"Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1\u03b1-hydroxylase expression in vitro. American Journal of Physiology -","volume":"293","author":"Perwad","year":"2007","journal-title":"Renal Physiology"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102170_b0340","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.ctrv.2021.102170_b0345","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1152\/ajprenal.90742.2008","article-title":"FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1","volume":"297","author":"Gattineni","year":"2009","journal-title":"First Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102170_b0350","article-title":"FGF\/FGFR signaling in health and disease. Signal Transduction and Targeted","volume":"5","author":"Xie","year":"2020","journal-title":"Therapy"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102170_b0355","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.7150\/jca.40531","article-title":"FGF\/FGFR signaling pathway involved resistance in various cancer types","volume":"11","author":"Zhou","year":"2020","journal-title":"Journal of Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102170_b0360","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discovery"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102170_b0365","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discovery"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102170_b0370","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102170_b0375","doi-asserted-by":"crossref","first-page":"a004002","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harbor Mol Case Stud"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102170_b0380","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102170_b0385","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102170_b0390","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1535-7163.MCT-14-0248","article-title":"The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284\/Debio 1347, a Novel Selective FGFR Inhibitor","volume":"13","author":"Nakanishi","year":"2014","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:24:27Z","timestamp":1759656267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":78,"alternative-id":["S0305737221000189"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102170","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting FGFR inhibition in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102170"}}